Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
52
NEO Quote, Financials, Valuation and Earnings
Last price:
$11.75
Seasonality move
:
40.74%
Day range:
$11.72 - $12.28
52-week range:
$4.72 - $19.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.12x
P/B ratio:
1.82x
Volume:
1.3M
Avg. volume:
1.8M
1-year change:
-28.64%
Market cap:
$1.5B
Revenue:
$660.6M
EPS (TTM):
-$0.89
Analysts' Opinion
-
Consensus RatingNeoGenomics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.94, NeoGenomics, Inc. has an estimated upside of 18.52% from its current price of $11.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $11.76.
Fair Value
-
According to the consensus of 11 analysts, NeoGenomics, Inc. has 18.52% upside to fair value with a price target of $13.94 per share.
NEO vs. S&P 500
-
Over the past 5 trading days, NeoGenomics, Inc. has underperformed the S&P 500 by -4.15% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NeoGenomics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NeoGenomics, Inc. has grown year-over-year revenues for 15 quarters straight. In the most recent quarter NeoGenomics, Inc. reported revenues of $187.8M.
Earnings Growth
-
NeoGenomics, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter NeoGenomics, Inc. reported earnings per share of -$0.21.
Enterprise value:
1.8B
EV / Invested capital:
--
Price / LTM sales:
2.12x
EV / EBIT:
--
EV / Revenue:
2.58x
PEG ratio (5yr expected):
-0.30x
EV / Free cash flow:
-107.26x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$290.1M
Return On Assets:
-7.42%
Net Income Margin (TTM):
-16%
Return On Equity:
-12.92%
Return On Invested Capital:
-8.07%
Operating Margin:
-7.55%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $574.8M | $644.1M | $709.2M | $167.8M | $187.8M | |
| Gross Profit | $218.3M | $261.3M | $290.1M | $71.4M | $77.4M | |
| Operating Income | -$104.1M | -$86.1M | -$73.6M | -$20.2M | -$14.2M | |
| EBITDA | -$24.8M | -$13.4M | -$4M | -$2.2M | $2.3M | |
| Diluted EPS | -$0.77 | -$0.62 | -$0.89 | -$0.14 | -$0.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $709.9M | $603.4M | $587M | $590.2M | $382.3M | |
| Total Assets | $1.9B | $1.8B | $1.7B | $1.6B | $1.4B | |
| Current Liabilities | $92.7M | $85M | $92.9M | $296.4M | $97.9M | |
| Total Liabilities | $769.1M | $742.6M | $730.8M | $732.9M | $536.5M | |
| Total Equity | $1.1B | $1B | $947.4M | $908.2M | $838.3M | |
| Total Debt | $605.8M | $605.2M | $599.5M | $602.6M | $405.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$23.4M | $15M | $13.7M | $9.2M | $8.9M | |
| Cash From Investing | $58.4M | $35.5M | -$11.5M | -$3.5M | -$277K | |
| Cash From Financing | $5.1M | $5.2M | -$200M | $1.2M | $765K | |
| Free Cash Flow | -$49.7M | -$21.5M | -$17M | -$1.6M | $570K | |
NEO
Sector
Market Cap
$1.5B
$27.6M
Price % of 52-Week High
61.52%
50.06%
Dividend Yield
0%
0%
Shareholder Yield
3.82%
-1.55%
1-Year Price Total Return
-28.64%
-18.12%
Beta (5-Year)
1.573
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$12.19
200-day SMA
Buy
Level
$8.68
Bollinger Bands (100)
Buy
Level
7.66 - 11.5
Chaikin Money Flow
Buy
Level
98.3M
20-day SMA
Sell
Level
$11.99
Relative Strength Index (RSI14)
Buy
Level
50.17
ADX Line
Buy
Level
27.9
Williams %R
Neutral
Level
-74.359
50-day SMA
Buy
Level
$11.17
MACD (12, 26)
Buy
Level
0.28
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
187.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9185)
Buy
CA Score
(Annual)
Level (-0.2492)
Buy
Beneish M-Score
(Annual)
Level (-2.6468)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (0.13)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Stock Forecast FAQ
In the current month, NEO has received 4 Buy ratings 7 Hold ratings, and 0 Sell ratings. The NEO average analyst price target in the past 3 months is $13.94.
-
Where Will NeoGenomics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that NeoGenomics, Inc. share price will rise to $13.94 per share over the next 12 months.
-
What Do Analysts Say About NeoGenomics, Inc.?
Analysts are divided on their view about NeoGenomics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NeoGenomics, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is NeoGenomics, Inc.'s Price Target?
The price target for NeoGenomics, Inc. over the next 1-year time period is forecast to be $13.94 according to 11 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is NEO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NeoGenomics, Inc. is a Hold. 7 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NEO?
You can purchase shares of NeoGenomics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NeoGenomics, Inc. shares.
-
What Is The NeoGenomics, Inc. Share Price Today?
NeoGenomics, Inc. was last trading at $11.75 per share. This represents the most recent stock quote for NeoGenomics, Inc.. Yesterday, NeoGenomics, Inc. closed at $11.76 per share.
-
How To Buy NeoGenomics, Inc. Stock Online?
In order to purchase NeoGenomics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NEO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NEO
Sector
P/E ratio
--
23.89x
PEG ratio
-0.30x
-0.01x
P/B ratio
1.82x
1.81x
Price / LTM sales
2.12x
1.58x
Growth Metrics
NEO
Sector
Revenue growth
11.9%
4.6%
Earnings growth
-51.58%
10.88%
Revenue (5-year growth)
10.07%
6.46%
Earnings forecast
$0.04
-$0.18
Profitability
NEO
Sector
Profitability FY 2024
$256.7M
$3.6M
Return on invested capital
-8.07%
-31.84%
Return on assets
-7.42%
-27.96%
Return on equity
-12.92%
-37.63%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Feb
17
Estimated Next Earnings Date
Jan
27
Balance Sheet
NEO
Sector
Total cash
$164.1M
$26.3M
Short term investments
$19.8M
$25.7M
Total assets
$1.6B
$78M
Long term debt
$405.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
